Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.33 |
| ▸ | BACE1 | P56817 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pirepemat SCHEMBL30149945 | 1.00 | HDAC4 (0.36) | HDAC4SIGMAR1SLC6A2SLC6A4HTR2A | |
| Pirepemat SCHEMBL30149946 | 1.00 | HDAC4 (0.36) | HDAC4SIGMAR1SLC6A2SLC6A4HTR2A | |
| Pirepemat SCHEMBL2421535 | 1.00 | HDAC4 (0.36) | HDAC4SIGMAR1SLC6A2SLC6A4HTR2A | |
| Pirepemat SCHEMBL20563768 | 1.00 | HDAC4 (0.36) | HDAC4SIGMAR1SLC6A2SLC6A4HTR2A | |
| Pirepemat SCHEMBL28959986 | 0.92 | HDAC4 (0.37) | HDAC4SIGMAR1SLC6A2SLC6A4HTR2A | |
| Pirepemat SCHEMBL28355846 | 0.92 | HDAC4 (0.40) | HDAC4SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| Pirepemat SCHEMBL28883051 | 0.89 | HDAC4 (0.38) | HDAC4SIGMAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1329993 | 0.87 | SLC6A2 (0.37) | HDAC4SLC6A2SLC6A4SLC6A3HTR1A | |
| SCHEMBL2422322 | 0.85 | BACE1 (0.35) | SIGMAR1SLC6A2SLC6A4HTR2AHTR2C | |
| SCHEMBL23918954 | 0.78 | OPRM1 (0.33) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4734984-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A FUMARIC ACID SALT OF (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE | Integrative Research Laboratories Sweden AB (SE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4734984-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A FUMARIC ACID SALT OF (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE | Integrative Research Laboratories Sweden AB (SE) | 2026-05-06 | — | — | EP | disclosed |
| CN-121511083-A | Pharmaceutical composition comprising fumarate salt of (+) -3- (2, 3-difluorophenyl) -3-methoxypyrrolidine | 综合研究实验室瑞典股份公司 | 2026-02-10 | — | — | CN | disclosed |
| WO-2025003437-A1 | A PHARMACEUTICAL COMPOSITION COMPRISING A FUMARIC ACID SALT OF (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE | INTEGRATIVE RESEARCH LABORATORIES SWEDEN AB (SE) | 2025-01-02 | — | — | WO | disclosed |
| US-20240400505-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | INTEGRATIVE RES LABORATORIES SWEDEN AB (SE) | 2024-12-05 | — | — | US | disclosed |
| CN-110621659-B | (+) -3- (2,3-difluorophenyl) -3-methoxy pyrrolidine or pharmaceutically acceptable salt thereof, preparation method and application thereof | 综合研究实验室瑞典股份公司 | 2023-02-28 | — | — | CN | disclosed |
| CN-110621659-B | (+) -3- (2,3-difluorophenyl) -3-methoxy pyrrolidine or pharmaceutically acceptable salt thereof, preparation method and application thereof | 综合研究实验室瑞典股份公司 | 2023-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400505-A1 | (+)-3-(2,3-DIFLUOROPHENYL)-3-METHOXYPYRROLIDINE OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, A PROCESS FOR PREPARATION THEREOF AND USES THEREOF | FIP1L1, CYP2C9, QDPR | HDAC4 3949/4885SIGMAR1 1258/4885SLC6A2 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.